1. Liu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. Curr Opin Rheumatol 2021;33:155–162.

2. Smatti MK, Cyprian FS, Nasrallah GK, Al Thani AA, Almishal RO, Yassine HM. Viruses and autoimmunity: a review on the potential interaction and molecular mechanisms. Viruses 2019;11:762.

3. Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 cytokine storm; what we know so far. Front Immunol 2020;11:1446.

4. Baglaenko Y, Chang NH, Johnson SR, et al. The presence of anti-nuclear antibodies alone is associated with changes in B cell activation and T follicular helper cells similar to those in systemic autoimmune rheumatic disease. Arthritis Res Ther 2018;20:264.

5. Esmaeilzadeh A, Elahi R. Immunobiology and immunotherapy of COVID-19: a clinically updated overview. J Cell Physiol 2021;236:2519–2543.

6. COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines [Internet] Bethesda (MD): National Institutes of Health, 2020. [cited 2022 Oct 26]. Available from: https://www.covid19treatmentguidelines.nih.gov/ . 7. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47:1245–1251.

8. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 2019;78:1151–1159.

9. Zhou Y, Han T, Chen J, et al. Clinical and autoimmune characteristics of severe and critical cases of COVID-19. Clin Transl Sci 2020;13:1077–1086.

10. Sacchi MC, Tamiazzo S, Stobbione P, et al. SARS-CoV-2 infection as a trigger of autoimmune response. Clin Transl Sci 2021;14:898–907.

11. Lerma LA, Chaudhary A, Bryan A, Morishima C, Wener MH, Fink SL. Prevalence of autoantibody responses in acute coronavirus disease 2019 (COVID-19). J Transl Autoimmun 2020;3:100073.

12. Pascolini S, Vannini A, Deleonardi G, et al. COVID-19 and immunological dysregulation: can autoantibodies be useful? Clin Transl Sci 2021;14:502–508.

13. Gagiannis D, Steinestel J, Hackenbroch C, et al. Clinical, serological, and histopathological similarities between severe COVID-19 and acute exacerbation of connective tissue disease-associated interstitial lung disease (CTD-ILD). Front Immunol 2020;11:587517.

14. Chang SH, Minn D, Kim YK. Autoantibodies in moderate and critical cases of COVID-19. Clin Transl Sci 2021;14:1625–1626.

15. Xavier RM, Yamauchi Y, Nakamura M, et al. Antinuclear antibodies in healthy aging people: a prospective study. Mech Ageing Dev 1995;78:145–154.

16. Nisihara R, Kubis MM, Rodrigues PC, Skare T, Mocelin V, Utiyama S. Antinuclear antibodies and rheumatoid factor positivity in healthy elderly adults: a cross-sectional study in 336 individuals. J Am Geriatr Soc 2013;61:2044–2046.

17. Nisihara R, Machoski MCC, Neppel A, Maestri CA, Messias-Reason I, Skare TL. Anti-nuclear antibodies in patients with breast cancer. Clin Exp Immunol 2018;193:178–182.

18. Gauderon A, Roux-Lombard P, Spoerl D. Antinuclear antibodies with a homogeneous and speckled immunofluorescence pattern are associated with lack of cancer while those with a nucleolar pattern with the presence of cancer. Front Med (Lausanne) 2020;7:165.

19. Michielsens B, Walravens M, Vermylen J, Carton H. Diagnostic significance of antinuclear antibodies in neurologic patients. Acta Neurol Scand 1991;84:102–106.

20. Feghali-Bostwick CA, Gadgil AS, Otterbein LE, et al. Autoantibodies in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177:156–163.

21. Ghrairi N, Aouadi S, Elhechmi YZ, Ben Saad S, Ben Ali I, Yalaoui S. Antinuclear antibodies in interstitial lung disease: prevalence and clinical significance. Tunis Med 2019;97:1240–1245.

22. Kim L, Garg S, O’Halloran A, et al. Risk factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the US coronavirus disease 2019 (COVID-19)-associated hospitalization surveillance network (COVID-NET). Clin Infect Dis 2021;72:e206–e214.

23. Dessie ZG, Zewotir T. Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infect Dis 2021;21:855.

24. Taeschler P, Cervia C, Zurbuchen Y, et al. Autoantibodies in COVID-19 correlate with antiviral humoral responses and distinct immune signatures. Allergy 2022;77:2415–2430.

25. Peker BO, Şener AG, Kaptan Aydoğmuş F. Antinuclear antibodies (ANAs) detected by indirect immunofluorescence (IIF) method in acute COVID-19 infection; future roadmap for laboratory diagnosis. J Immunol Methods 2021;499:113174.

26. Berger JS, Kunichoff D, Adhikari S, et al. Prevalence and outcomes of D-dimer elevation in hospitalized patients with COVID-19. Arterioscler Thromb Vasc Biol 2020;40:2539–2547.

27. Biran N, Ip A, Ahn J, et al. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. Lancet Rheumatol 2020;2:e603–e612.

28. Schiffrin EL, Flack JM, Ito S, Muntner P, Webb RC. Hypertension and COVID-19. Am J Hypertens 2020;33:373–374.

29. Meena P, Bhargava V, Rana DS, Bhalla AK, Gupta A. COVID-19 and the kidney: a matter of concern. Curr Med Res Pract 2020;10:165–168.

30. Rubin S, Orieux A, Prevel R, et al. Characterization of acute kidney injury in critically ill patients with severe coronavirus disease 2019. Clin Kidney J 2020;13:354–361.

31. Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 2020;97:829–838.